AI assistant
VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2021
Feb 16, 2021
29864_dirs_2021-02-16_a4915c6a-bd23-4c9c-8953-b27869693e38.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2021-02-11
Reporting Person: Sanna Bastiano (EVP, Cell & Genetic Therapies)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-02-11 | Common Stock | S | 1469 | $210.44 | Disposed | 39081 | Direct |
| 2021-02-11 | Common Stock | S | 217 | $211.41 | Disposed | 38864 | Direct |
Footnotes
F1: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $210.44 (range $210.06 to $210.90).
F3: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $211.41 (range $211.17 to $211.50).